129 related articles for article (PubMed ID: 18644722)
1. Synthesis and evaluation of acylguanidine FXa inhibitors.
O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
[TBL] [Abstract][Full Text] [Related]
2. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
3. Anthranilamide inhibitors of factor Xa.
Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
[TBL] [Abstract][Full Text] [Related]
4. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
[TBL] [Abstract][Full Text] [Related]
6. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ
Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239
[TBL] [Abstract][Full Text] [Related]
7. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
9. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
[TBL] [Abstract][Full Text] [Related]
10. Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury.
Zhang R; Lei L; Xu YG; Hua WY; Gong GQ
Bioorg Med Chem Lett; 2007 May; 17(9):2430-3. PubMed ID: 17346962
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
12. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
13. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
Bauer SM; Goldman EA; Huang W; Su T; Wang L; Woolfrey J; Wu Y; Zuckett JF; Arfsten A; Huang B; Kothule J; Lin J; May B; Sinha U; Wong PW; Hutchaleelaha A; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2004 Aug; 14(15):4045-50. PubMed ID: 15225723
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.
Siles R; Chen SE; Zhou M; Pinney KG; Trawick ML
Bioorg Med Chem Lett; 2006 Aug; 16(16):4405-9. PubMed ID: 16781147
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
17. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I).
Zheng J; Wen R; Luo X; Lin G; Zhang J; Xu L; Guo L; Jiang H
Bioorg Med Chem Lett; 2006 Jan; 16(1):225-7. PubMed ID: 16246548
[TBL] [Abstract][Full Text] [Related]
19. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor.
Kohrt JT; Bigge CF; Bryant JW; Casimiro-Garcia A; Chi L; Cody WL; Dahring T; Dudley DA; Filipski KJ; Haarer S; Heemstra R; Janiczek N; Narasimhan L; McClanahan T; Peterson JT; Sahasrabudhe V; Schaum R; Van Huis CA; Welch KM; Zhang E; Leadley RJ; Edmunds JJ
Chem Biol Drug Des; 2007 Aug; 70(2):100-12. PubMed ID: 17683371
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
